Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI Neoadjuvant Therapy for LARC
NCT02942563Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin and irinotecan in rectal cancer, sponsored by Renji Hospital. Primary endpoint: Pelvic complete resection rate at 10 weeks. Status: unknown.
02
Drugs
fluorouraciloxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02942563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942563.